Breaking News Instant updates and real-time market news.

GBT

Global Blood Therapeutics

$19.15

0.5 (2.68%)

16:08
11/30/16
11/30
16:08
11/30/16
16:08

Global Blood Therapeutics announces upcoming webcast to review GBT440 Data

Global Blood Therapeutics announced that it will host an investor webcast on Monday, December 5, 2016, at 12:15 p.m. PT/3:15 p.m. ET, to review new data being presented at the 58th American Society of Hematology, ASH, Annual Meeting & Exposition Conference in San Diego that support its GBT440 program in sickle cell disease. The investor event will feature members of GBT's management team and SCD experts Dr. Jo Howard of Guy's and St. Thomas' NHS Foundation Trust, London, UK, Dr. Wally R. Smith of Virginia Commonwealth University, and Dr. Jeremy Hobart of Peninsula Schools of Medicine and Dentistry. The event will highlight data presented at the ASH meeting from GBT's ongoing Phase 1/2 GBT440-001 trial including results of dosing GBT440 at 900 mg per day in SCD patients for up to 6 months, and the metabolism of GBT440 in healthy subjects, as well as the methodology utilized to develop the Patient Reported Outcome tool that will be used in the Company's planned Phase 3 clinical trial of GBT440 in SCD patients, titled the HOPE Study.

  • 03

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

GBT Global Blood Therapeutics
$19.15

0.5 (2.68%)

09/30/16
WELS
09/30/16
INITIATION
WELS
Outperform
Global Blood Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Global Blood Therapeutics with an Outperform rating and $75-$81 price target range. The analyst has a positive outlook for the company's hemoglobin modifier GBT440 in Sickle Cell Disease. He views GBT440 as a best-in-class hemoglobin modifier and estimates peak sales at $2.7B.
10/25/16
COWN
10/25/16
NO CHANGE
Target $83
COWN
Outperform
Global Blood Therapeutics price target raised to $83 from $80 at Cowen
Cowen analyst Ritu Baral raised his price target on Global Blood Therapeutics to $83 from $80 after the company reached a deal with the FDA regarding the design of its pivotal trial for GBT440 for sickle cell. Baral reiterated his Outperform rating on Global Therapeutics shares.
11/01/16
ROTH
11/01/16
INITIATION
Target $47
ROTH
Buy
Global Blood Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach started Global Blood Therapeutics with a Buy rating and $47 price target, saying it represents an attractive investment opportunity as he believes its lead product, GBT440, has the potential to improve the standard of care for patients who suffer from Sickle Cell Anemia.
11/04/16
ROTH
11/04/16
NO CHANGE
Target $47
ROTH
Buy
Global Blood weakness on ASH abstracts unjustified, says Roth Capital
Roth Capital analyst Mark Breidenbach believes Global Blood Therapeutics' GBT440 has the potential to markedly improve the standard of care for patients who suffer from sickle cell anemia. With an upcoming readout expected at ASH that could significantly de-risk the company's planned pivotal trial, the analyst believes Global Blood Therapeutics represents an "excellent investment opportunity." Further, Breidenbach notes that the shares' weakness following the publication of abstracts for the upcoming 2016 ASH meeting seems to be unjustified. He says Global Blood Therapeutics remains a Focus Pick, and reiterates a Buy rating and $47 price target on the shares.

TODAY'S FREE FLY STORIES

FCX

Freeport McMoRan

$14.91

-0.16 (-1.06%)

05:37
02/21/17
02/21
05:37
02/21/17
05:37
Initiation
Freeport McMoRan initiated  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SOHU

Sohu.com

$39.35

0.1 (0.25%)

05:36
02/21/17
02/21
05:36
02/21/17
05:36
Earnings
Sohu.com sees Q1 EPS ($1.80)-($1.55), consensus ($1.59) »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SEMG

SemGroup

$40.05

0.15 (0.38%)

05:34
02/21/17
02/21
05:34
02/21/17
05:34
Initiation
SemGroup initiated  »

SemGroup reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SOHU

Sohu.com

$39.35

0.1 (0.25%)

05:34
02/21/17
02/21
05:34
02/21/17
05:34
Earnings
Sohu.com reports Q4 EPS ($1.79), consensus ($2.08) »

Reports Q4 revenue $412M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

JELD

JELD-WEN Holding

$29.48

0.48 (1.66%)

05:33
02/21/17
02/21
05:33
02/21/17
05:33
Initiation
JELD-WEN Holding initiated  »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REVG

REV Group

$27.59

0.37 (1.36%)

05:32
02/21/17
02/21
05:32
02/21/17
05:32
Initiation
REV Group initiated  »

REV Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REVG

REV Group

$27.59

0.37 (1.36%)

05:32
02/21/17
02/21
05:32
02/21/17
05:32
Initiation
REV Group initiated  »

REV Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:30
02/21/17
02/21
05:30
02/21/17
05:30
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:30
02/21/17
02/21
05:30
02/21/17
05:30
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:29
02/21/17
02/21
05:29
02/21/17
05:29
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:28
02/21/17
02/21
05:28
02/21/17
05:28
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:28
02/21/17
02/21
05:28
02/21/17
05:28
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAG

Jagged Peak Energy

$13.50

-0.08 (-0.59%)

05:26
02/21/17
02/21
05:26
02/21/17
05:26
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFLYY

Air France-KLM

$6.83

0.29 (4.43%)

05:25
02/21/17
02/21
05:25
02/21/17
05:25
Upgrade
Air France-KLM rating change  »

Air France-KLM upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENGGY

Enagas

$12.34

-0.0699 (-0.56%)

05:24
02/21/17
02/21
05:24
02/21/17
05:24
Downgrade
Enagas rating change  »

Enagas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRBP

Corbus Pharmaceuticals

$8.85

0.55 (6.63%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
Cantor Fitzgerald health/pharma analysts hold analyst/industry conference call »

Analysts, along with Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
CLSA automotive analyst holds an analyst/industry conference call »

Analyst Rosner, along…

AGR

AVANGRID

$40.91

0.13 (0.32%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
AVANGRID to hold a financial update »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 28

    Feb

LHCG

LHC Group

$48.30

0.12 (0.25%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
LHC Group management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 21

    Mar

HNI

HNI Corporation

$46.09

0.04 (0.09%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
HNI Corporation management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

KN

Knowles

$19.42

0.14 (0.73%)

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
Knowles management to meet with Roth Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

04:55
02/21/17
02/21
04:55
02/21/17
04:55
General news
Breaking General news story  »

Philadelphia Federal…

04:55
02/21/17
02/21
04:55
02/21/17
04:55
General news
Breaking General news story  »

San Francisco Federal…

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
UBS to hold a field trip »

UBS Telecom Trip to…

04:55
02/21/17
02/21
04:55
02/21/17
04:55
Conference/Events
DA Davidson technology/software analysts hold analyst/industry conference call »

Technology Analyst…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.